Show simple item record

dc.contributor.authorSigurdardottir, Sigurveig Th
dc.contributor.authorCenter, Kimberly J
dc.contributor.authorDavidsdottir, Katrin
dc.contributor.authorArason, Vilhjalmur A
dc.contributor.authorHjalmarsson, Bjorn
dc.contributor.authorElisdottir, Ragnheidur
dc.contributor.authorIngolfsdottir, Gunnhildur
dc.contributor.authorNorthington, Robert
dc.contributor.authorScott, Daniel A
dc.contributor.authorJonsdottir, Ingileif
dc.date.accessioned2014-09-01T15:40:18Z
dc.date.available2014-09-01T15:40:18Z
dc.date.issued2014-01-09
dc.date.submitted2014
dc.identifier.citationVaccine 2014, 32 (3):417-24en
dc.identifier.issn1873-2518
dc.identifier.pmid24300594
dc.identifier.doi10.1016/j.vaccine.2013.11.029
dc.identifier.urihttp://hdl.handle.net/2336/325595
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractPneumococcal polysaccharide vaccine (PPV) is used in children at high risk of IPD. PPV is generally not considered to induce immunologic memory, whereas pneumococcal conjugate vaccines (PCVs) elicit protective antibody responses in infants and induce immunologic memory. Little is known about the characteristics of immune responses to PCV in children who previously received PCV and PPV in series.
dc.description.abstractTo characterize immune responses to 13-valent pneumococcal CRM197 conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in children vaccinated in infancy with 9-valent pneumococcal-meningococcal C-CRM197 conjugate combination vaccine (PCV9-MnCC), followed by a toddler dose of PCV9-MnCC or 23-valent pneumococcal polysaccharide vaccine (PPV23).
dc.description.abstractChildren (n=89) who received PCV9-MnCC in infancy and PPV23 or PCV9-MnCC at age 12 months in a previous (2002-2003) study were vaccinated at age 7.5 years with PCV13; groups PPV23/PCV13 (n=50) and PCV9/PCV13 (n=39). Immunoglobulin (Ig)G antibodies, avidity, and opsonophagocytic activity (OPA) were measured before and at 1 and 4 weeks postvaccination.
dc.description.abstractOne week postvaccination, IgG levels increased significantly for all serotypes in both groups, and >97% of vaccinees achieved IgG ≥0.35μg/ml 4 weeks after PCV13 vaccination. The PCV9/PCV13 group had higher IgG responses compared with the PPV23/PCV13 group. The upper limits of the 95% confidence intervals of the PPV23/PCV13:PCV9/PCV13 IgG geometric mean concentration ratios were <1.0 for serotypes 1, 4, 5, 9V, 18C, and 23F at 1 week. OPA and avidity results supported these findings.
dc.description.abstractPPV23 vaccination of toddlers may compromise subsequent responses to pneumococcal conjugate vaccines. The clinical relevance of this finding is unclear.
dc.description.sponsorshipPfizer Inc. Wyeth Pfizeren
dc.language.isoenen
dc.publisherElsevier Science Ltd.en
dc.relation.urlhttp://dx.doi.org/10.1016/j.vaccine.2013.11.029en
dc.rightsArchived with thanks to Vaccineen
dc.subjectLungnabólgaen
dc.subjectBóluefnien
dc.subject.meshAntibodies, Bacterialen
dc.subject.meshAntibody Affinityen
dc.subject.meshChilden
dc.subject.meshDrug Interactionsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunoglobulin Gen
dc.subject.meshMaleen
dc.subject.meshOpsonin Proteinsen
dc.subject.meshPhagocytosisen
dc.subject.meshPneumococcal Vaccinesen
dc.subject.meshVaccines, Conjugateen
dc.titleDecreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.en
dc.typeArticleen
dc.contributor.departmentNatl Univ Hosp Iceland, Dept Immunol, Landspitali, IS-101 Reykjavik, Iceland, Univ Iceland, Fac Med, Reykjavik, Iceland, Pfizer Inc, Collegeville, PA 19426 USA, Pfizer Inc, Pearl River, NY 10965 USA, Ctr Child Hlth Serv, Primary Hlth Care Reykjavik Capital Area, IS-109 Reykjavik, Icelanden
dc.identifier.journalVaccineen
dc.rights.accessNational Consortium - Landsaðganguren
html.description.abstractPneumococcal polysaccharide vaccine (PPV) is used in children at high risk of IPD. PPV is generally not considered to induce immunologic memory, whereas pneumococcal conjugate vaccines (PCVs) elicit protective antibody responses in infants and induce immunologic memory. Little is known about the characteristics of immune responses to PCV in children who previously received PCV and PPV in series.
html.description.abstractTo characterize immune responses to 13-valent pneumococcal CRM197 conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in children vaccinated in infancy with 9-valent pneumococcal-meningococcal C-CRM197 conjugate combination vaccine (PCV9-MnCC), followed by a toddler dose of PCV9-MnCC or 23-valent pneumococcal polysaccharide vaccine (PPV23).
html.description.abstractChildren (n=89) who received PCV9-MnCC in infancy and PPV23 or PCV9-MnCC at age 12 months in a previous (2002-2003) study were vaccinated at age 7.5 years with PCV13; groups PPV23/PCV13 (n=50) and PCV9/PCV13 (n=39). Immunoglobulin (Ig)G antibodies, avidity, and opsonophagocytic activity (OPA) were measured before and at 1 and 4 weeks postvaccination.
html.description.abstractOne week postvaccination, IgG levels increased significantly for all serotypes in both groups, and >97% of vaccinees achieved IgG ≥0.35μg/ml 4 weeks after PCV13 vaccination. The PCV9/PCV13 group had higher IgG responses compared with the PPV23/PCV13 group. The upper limits of the 95% confidence intervals of the PPV23/PCV13:PCV9/PCV13 IgG geometric mean concentration ratios were <1.0 for serotypes 1, 4, 5, 9V, 18C, and 23F at 1 week. OPA and avidity results supported these findings.
html.description.abstractPPV23 vaccination of toddlers may compromise subsequent responses to pneumococcal conjugate vaccines. The clinical relevance of this finding is unclear.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record